Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AOH 1996

X
Drug Profile

AOH 1996

Alternative Names: AOH-1996

Latest Information Update: 13 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; RLL LLC
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proliferating cell nuclear antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 02 Jan 2025 City of Hope Medical Center plans a phase I/Ib for Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy, Recurrent) in USA(PO) in August 2025 (NCT06763341)
  • 10 Dec 2024 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) prior to December 2024
  • 10 Dec 2024 Pharmacodynamics data from a preclinical study in Acute myeloid leukaemia released by City of Hope National Medical Center

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top